Comparative Pharmacology
Head-to-head clinical analysis: MOXEZA versus PROQUIN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOXEZA versus PROQUIN XR.
MOXEZA vs PROQUIN XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination.
Fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
400 mg orally once daily with or without food.
500 mg orally once daily with food.
None Documented
None Documented
Terminal half-life: 12 hours; allows once-daily dosing
Terminal elimination half-life is approximately 10-14 hours in patients with normal renal function (CrCl >80 mL/min). Extended half-life may occur in renal impairment, necessitating dose adjustment.
Renal: 70% unchanged; biliary/fecal: 20%; metabolized: 10%
Primarily renal excretion of unchanged drug (~60-80%) via glomerular filtration and tubular secretion. Biliary/fecal excretion accounts for approximately 20-35%, with a small portion as metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic